Catheter-based renal sympathetic denervation: A targeted approach to resistant hypertension

Cardiology Journal

Volumn 18, Issue 1, 2011, Pages 97-102

  Gewirtz, Janna R ^a   Bisognano, John D ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; BASEMENT MEMBRANE; CATHETER; CATHETER ABLATION; CELL MEMBRANE; DEVICE; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY INNERVATION; KIDNEY TUBULE EPITHELIUM; MICROVASCULATURE; MINIMALLY INVASIVE SURGERY; NERVE CELL NETWORK; PATHOGENESIS; SAFETY; SMOOTH MUSCLE FIBER; SPINAL GANGLION; SYMPATHETIC NERVE CELL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VASCULAR ACCESS; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CATHETER ABLATION; DRUG RESISTANCE; HUMANS; HYPERTENSION; KIDNEY; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 79951495079     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lloyd-Jones D, Adams RJ, Brown TM et al. Executive summary: heart disease and stroke statistics: 2010 update. A report from the American Heart Association. Circulation, 2010; 121: 948-954.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension. Analysis of worldwide data. Lancet, 2005; 365: 217-223.
3. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension. A multicentre safety and proof-of-principle cohort study. Lancet, 2009; 373: 1275-1281.
4. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment- resistant hypertension (the Symplicity Htn-2 Trial). A randomised controlled trial. Lancet, 2010; 376: 1903-1909.
5. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol, 2010; 105: 570-576.
6. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation, 2008; 117: e510-e526.
7. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens, 2002; 11: 197-200.
8. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev, 1997; 77: 75-197.
9. Esler M, Jennings G, Korner P et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension, 1988; 11: 3-20.
10. Schlaich MP, Lambert E, Kaye DM et al. Sympathetic augmentation in hypertension. Role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension, 2004; 43: 169-175.
11. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension: Review of 122 cases. Lancet, 1953; 1: 403-408.
12. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: Results in 1,266 cases. J Am Med Assoc, 1953; 152: 1501-1504.
13. Evelyn KA, Singh MM, Chapman WP, Perera GA, Thaler H. Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med, 1960; 28: 188-221.
14. DiBona GF. Neural control of the kidney: Past, present, and future. Hypertension, 2003; 41: 621-624.
15. Barajas L, Muller J. The innervation of the juxtaglomerular apparatus and surrounding tubules. A quantitative analysis by serial section electron microscopy. J Ultrastruct Res, 1973; 43: 107-132.
16. Barajas L, Liu L, Powers K. Anatomy of the renal innervation: Intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol, 1992; 70: 735-749.
17. Luff SE, Hengstberger SG, McLachlan EM, Anderson WP. Distribution of sympathetic neuroeffector junctions in the juxtaglomerular region of the rabbit kidney. J Auton Nerv Syst, 1992; 40: 239-253.
18. Esler M, Jennings G, Lambert G. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens, 1989; 2: 140S-146S.
19. Kopp UC, Cicha MZ, Smith LA, Mulder J, Hokfelt T. Renal sympathetic nerve activity modulates afferent renal nerve activity by pge2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol, 2007; 293: R1561-R1572.
20. Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation, 2002; 106: 1974-1979.
21. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev, 1991; 71: 659-682.
22. Kopp UC, Cicha MZ, Nakamura K, Nusing RM, Smith LA, Hokfelt T. Activation of ep4 receptors contributes to prostaglandin e2-mediated stimulation of renal sensory nerves. Am J Physiol Renal Physiol, 2004; 287: F1269-F1282.
23. Kopp UC, Cicha MZ, Smith LA, Hokfelt T. Nitric oxide modulates renal sensory nerve fibers by mechanisms related to substance p receptor activation. Am J Physiol Regul Integr Comp Physiol, 2001; 281: R279-R290.
24. Liu L, Barajas L. The rat renal nerves during development. Anat Embryol (Berl), 1993; 188: 345-361.
25. Calaresu FR, Ciriello J. Renal afferent nerves affect discharge rate of medullary and hypothalamic single units in the cat. J Auton Nerv Syst, 1981; 3: 311-320.
26. Ciriello J. Afferent renal inputs to paraventricular nucleus vasopressin and oxytocin neurosecretory neurons. Am J Physiol, 1998; 275: R1745-R1754.
27. Caverson MM, Ciriello J. Effect of stimulation of afferent renal nerves on plasma levels of vasopressin. Am J Physiol, 1987; 252: R801-R807.
28. Hoobler SW, Manning JT, Paine WG et al. The effects of splanchnicectomy on the blood pressure in hypertension: A controlled study. Circulation, 1951; 4: 173-183.
29. Smithwick RH. Hypertensive vascular disease: Results of and indications for splanchnicectomy. J Chronic Dis, 1955; 1: 477-496.
30. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med, 2009; 361: 932-934.
31. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: Novel implications for an old concept. Hypertension, 2009; 54: 1195-1201.
32. Cappato R, Calkins H, Chen SA et al. Prevalence and causes of fatal outcomes in catheter ablation of atrial fibrillation. J Am Coll Cardiol, 2009; 53: 1798-1803.
33. Belhassen B. A 1 per 1,000 mortality rate after catheter ablation of atrial fibrillation: An acceptable risk? J Am Coll Cardiol, 2009; 53: 1804-1806.